Concerns and Legal Battles Over GLP-1 Drugs

Todd Engel, a seasoned heavy machinery operator in Maryland, faced a devastating health crisis in early 2023. After decades working around warehouses and highways, his doctor prescribed Ozempic, a GLP-1 drug, for diabetes. On New Year’s Eve, he awoke with vision loss in his right eye, described as having a dark patch. His doctor diagnosed it as nonarteritic anterior ischemic optic neuropathy (NAION), an inoperable condition due to reduced blood flow to the eye.

Although Ozempic had not been linked to this condition at the time, Engel’s wife, Shelley, questioned its involvement. Research published seven months later in JAMA Ophthalmology indicated higher rates of NAION in diabetic patients on Ozempic, known generically as semaglutide. However, unaware of this, Engel continued his treatment until he lost vision in his left eye as well.

A Gallup analysis reports that more than one in ten Americans use GLP-1 drugs for weight loss, and many experience various side effects. Engel is now part of consolidated lawsuits alleging that Ozempic’s manufacturer, Novo Nordisk, failed to warn about NAION risks. Novo Nordisk counters these claims, citing subsequent research questioning the drug’s connection to NAION.

The crux of the legal battle is whether GLP-1 drugs caused this harm. Observational data suggests possible correlations but not direct causation, necessitating more investigative research. Despite critique from the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society, the potential link needs more exploration.

The Food and Drug Administration (FDA) maintains a database for adverse event reports related to pharmaceuticals, a crucial early step in prompting regulatory review. As of 2024, the database recorded over 1,000 reports of optic neuropathy linked to GLP-1s, among nearly 190,000 total reports. Most of these reports involve minor side effects.

Novo Nordisk asserts that serious conditions like NAION are rare in clinical trials and continues to update the FDA with post-market data. However, the FDA plans to assess the reported NAION risks independently.

Attorney Jonathan Orent, overseeing the major lawsuits, advocates for updated warning labels in the U.S., similar to Europe. His cases comprise numerous claims, including 247 with NAION and over 4,000 with digestive issues.

Engel reflects on the life changes caused by his blindness, lamenting the loss of everyday activities and family interactions. Dr. Mohammed Ali from Emory University hasn’t reported similar cases to the FDA, uncertain whether GLP-1 drugs are the direct cause.

The rise of online drug sales complicates matters. Pharmacist Robert Miller from West Texas Poison Control highlights how unsupervised online sales increase side effect reports, lacking medical oversight.

The legal and medical communities continue to discuss the implications, as plaintiffs like the Engels seek both damages and improved warning protocols. Shelley Engel believes transparency might have prevented her husband’s vision loss, lamenting the absence of effective warnings.